Johnson & Johnson's subcutaneous injection of dual antibodies has been approved for market in China, with the administration time reduced to approximately 5 minutes.

According to the Securities Times app, on December 25th, Johnson & Johnson (JNJ.US) announced that its innovative treatment drug, Alecensa - alectinib injection (subcutaneous injection), has officially been approved by the Chinese NMPA for the treatment of advanced non-small cell lung cancer (NSCLC) patients carrying epidermal growth factor receptor (EGFR) mutations. The subcutaneous injection formulation of alectinib provides patients with greater convenience, reducing the administration time from several hours to about 5 minutes, while also decreasing the incidence of infusion-related adverse reactions by 80% compared to intravenous injection formulations.